Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.

Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, Ferenczy A, Kurman RJ, Ronnett BM, Stoler MH, Bautista OM, Moeller E, Ritter M, Shields C, Luxembourg A.

Gynecol Oncol. 2019 Jul;154(1):110-117. doi: 10.1016/j.ygyno.2019.03.253. Epub 2019 Apr 11.

2.

Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine.

Guevara AM, Suarez E, Victoria A, Ngan HY, Hirschberg AL, Fedrizzi E, Bautista O, Shields C, Joshi A, Luxembourg A.

Hum Vaccin Immunother. 2019;15(1):141-145. doi: 10.1080/21645515.2018.1514227. Epub 2018 Sep 27.

3.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
4.

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.

Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A.

J Infect Dis. 2018 Jun 5;218(1):95-108. doi: 10.1093/infdis/jiy133.

5.

Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies.

Saah A, Bautista O, Luxembourg A, Perez G.

Contemp Clin Trials Commun. 2017 Jul 24;7:189-193. doi: 10.1016/j.conctc.2017.07.010. eCollection 2017 Sep.

6.

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.

Ruiz-Sternberg ÁM, Moreira ED Jr, Restrepo JA, Lazcano-Ponce E, Cabello R, Silva A, Andrade R, Revollo F, Uscanga S, Victoria A, Guevara AM, Luna J, Plata M, Dominguez CN, Fedrizzi E, Suarez E, Reina JC, Ellison MC, Moeller E, Ritter M, Shields C, Cashat M, Perez G, Luxembourg A.

Papillomavirus Res. 2018 Jun;5:63-74. doi: 10.1016/j.pvr.2017.12.004. Epub 2017 Dec 19.

7.

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.

Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A.

Hum Vaccin Immunother. 2018 Feb 1;14(2):396-403. doi: 10.1080/21645515.2017.1403700. Epub 2017 Dec 14.

8.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

9.

9-Valent human papillomavirus vaccine: a review of the clinical development program.

Luxembourg A, Moeller E.

Expert Rev Vaccines. 2017 Nov;16(11):1119-1139. doi: 10.1080/14760584.2017.1383158. Epub 2017 Oct 9. Review.

PMID:
28956458
10.

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.

Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5.

PMID:
28886907
11.

Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.

Guevara A, Cabello R, Woelber L, Moreira ED Jr, Joura E, Reich O, Shields C, Ellison MC, Joshi A, Luxembourg A.

Vaccine. 2017 Sep 5;35(37):5050-5057. doi: 10.1016/j.vaccine.2017.07.017. Epub 2017 Aug 5.

PMID:
28789851
12.

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.

Petersen LK, Restrepo J, Moreira ED Jr, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A.

Papillomavirus Res. 2017 Jun;3:105-115. doi: 10.1016/j.pvr.2017.03.002. Epub 2017 Mar 16.

14.

Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.

Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, Berkovitch M, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A.

JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615.

PMID:
27893068
15.

Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.

Luxembourg A, Kjaer SK, Nygard M, Ellison MC, Group T, Marshall JB, Radley D, Saah A.

Contemp Clin Trials. 2017 Jan;52:54-61. doi: 10.1016/j.cct.2016.10.006. Epub 2016 Oct 21.

PMID:
27777126
16.

Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.

Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A.

Pediatrics. 2016 Aug;138(2). pii: e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15.

17.

A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.

Van Damme P, Meijer CJLM, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M.

Vaccine. 2016 Jul 29;34(35):4205-4212. doi: 10.1016/j.vaccine.2016.06.056. Epub 2016 Jun 25.

18.

Additional Protection from 9-Valent HPV Vaccine if Administered Before HPV Exposure.

Joura E, Clark L, Luxembourg A.

Am Fam Physician. 2016 Feb 15;93(4):254-6. No abstract available.

19.

Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom.

Brown D, Kulkarni AS, Pillsbury M, Luxembourg A, Saah A.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1940-2. doi: 10.1080/21645515.2016.1143159. No abstract available.

20.

Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials.

Bautista OM, Luxembourg A.

Contemp Clin Trials. 2016 Mar;47:254-8. doi: 10.1016/j.cct.2016.01.002. Epub 2016 Jan 18.

PMID:
26795674
21.

Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.

Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A.

Vaccine. 2015 Nov 27;33(48):6855-64. doi: 10.1016/j.vaccine.2015.08.059. Epub 2015 Sep 26.

PMID:
26411885
22.

9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.

Pitisuttithum P, Velicer C, Luxembourg A.

Expert Rev Vaccines. 2015;14(11):1405-19. doi: 10.1586/14760584.2015.1089174. Epub 2015 Sep 14. Review.

PMID:
26366475
23.

Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.

Schilling A, Parra MM, Gutierrez M, Restrepo J, Ucros S, Herrera T, Engel E, Huicho L, Shew M, Maansson R, Caldwell N, Luxembourg A, Ter Meulen AS.

Pediatrics. 2015 Sep;136(3):e563-72. doi: 10.1542/peds.2014-4199. Epub 2015 Aug 3.

24.

Immunogenicity and safety of the 9-valent HPV vaccine in men.

Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, Luxembourg A, Kaplan SS.

Vaccine. 2015 Nov 27;33(48):6892-901. doi: 10.1016/j.vaccine.2015.06.088. Epub 2015 Jul 2.

PMID:
26144901
25.

A 9-Valent HPV Vaccine in Women.

Joura E, Bautista O, Luxembourg A.

N Engl J Med. 2015 Jun 25;372(26):2568-9. doi: 10.1056/NEJMc1504359. No abstract available.

PMID:
26107058
26.

Immunogenicity and Safety of a 9-Valent HPV Vaccine.

Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A.

Pediatrics. 2015 Jul;136(1):e28-39. doi: 10.1542/peds.2014-3745.

27.

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.

Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M.

Pediatr Infect Dis J. 2015 Sep;34(9):992-8. doi: 10.1097/INF.0000000000000773.

PMID:
26090572
28.

Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.

Luxembourg A, Moreira ED Jr, Samakoses R, Kim KH, Sun X, Maansson R, Moeller E, Christiano S, Chen J.

Hum Vaccin Immunother. 2015;11(6):1306-12. doi: 10.1080/21645515.2015.1009819.

29.

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.

Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J.

Hum Vaccin Immunother. 2015;11(6):1313-22. doi: 10.1080/21645515.2015.1012010.

30.

An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.

Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, Joura EA, Ciprero K, Maansson R, Luxembourg A, Sobanjo-ter Meulen A.

Pediatr Infect Dis J. 2015 Jun;34(6):627-34. doi: 10.1097/INF.0000000000000694.

PMID:
25831420
31.

Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.

Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J.

Contemp Clin Trials. 2015 May;42:18-25. doi: 10.1016/j.cct.2015.02.009. Epub 2015 Mar 3.

PMID:
25749310
32.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.

N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.

33.

Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J.

Hum Vaccin Immunother. 2014;10(8):2168-74. doi: 10.4161/hv.29205. Review.

34.

A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges.

Chen YH, Gesser R, Luxembourg A.

Clin Trials. 2015 Feb;12(1):84-90. doi: 10.1177/1740774514552110. Epub 2014 Oct 1.

PMID:
25278227
35.

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.

Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.

36.

In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.

Khawaja G, Buronfosse T, Jamard C, Abdul F, Guerret S, Zoulim F, Luxembourg A, Hannaman D, Evans CF, Hartmann D, Cova L.

Virology. 2012 Nov 10;433(1):192-202. doi: 10.1016/j.virol.2012.07.014. Epub 2012 Aug 24.

37.

Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.

Khawaja G, Buronfosse T, Jamard C, Guerret S, Zoulim F, Luxembourg A, Hannaman D, Evans C, Hartmann D, Cova L.

Virology. 2012 Mar 30;425(1):61-9. doi: 10.1016/j.virol.2012.01.001. Epub 2012 Jan 28.

38.

A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS.

Clin Vaccine Immunol. 2011 May;18(5):707-16. doi: 10.1128/CVI.00030-11. Epub 2011 Mar 30.

39.

Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks.

Liu KH, Ascenzi MA, Bellezza CA, Bezuidenhout AJ, Cote PJ, Gonzalez-Aseguinolaza G, Hannaman D, Luxembourg A, Evans CF, Tennant BC, Menne S.

J Virol. 2011 May;85(10):4853-62. doi: 10.1128/JVI.02437-10. Epub 2011 Mar 9.

40.

Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies.

van Drunen Littel-van den Hurk S, Lawman Z, Wilson D, Luxembourg A, Ellefsen B, van den Hurk JV, Hannaman D.

Vaccine. 2010 Sep 7;28(39):6445-54. doi: 10.1016/j.vaccine.2010.07.045. Epub 2010 Jul 27.

PMID:
20670907
41.

Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.

Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D.

Vaccine. 2010 Jan 22;28(4):1056-61. doi: 10.1016/j.vaccine.2009.10.111. Epub 2009 Nov 5.

PMID:
19896452
42.

Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle.

van Drunen Littel-van den Hurk S, Luxembourg A, Ellefsen B, Wilson D, Ubach A, Hannaman D, van den Hurk JV.

Vaccine. 2008 Oct 9;26(43):5503-9. doi: 10.1016/j.vaccine.2008.07.093. Epub 2008 Aug 15.

PMID:
18708108
43.

Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens.

Luxembourg A, Hannaman D, Wills K, Bernard R, Tennant BC, Menne S, Cote PJ.

Vaccine. 2008 Jul 29;26(32):4025-33. doi: 10.1016/j.vaccine.2008.05.021. Epub 2008 Jun 2.

PMID:
18556096
44.

Potentiation of an anthrax DNA vaccine with electroporation.

Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, Tellez O, Little S, Bernard R.

Vaccine. 2008 Sep 19;26(40):5216-22. doi: 10.1016/j.vaccine.2008.03.064. Epub 2008 Apr 16.

PMID:
18462850
45.

Electroporation-based DNA immunisation: translation to the clinic.

Luxembourg A, Evans CF, Hannaman D.

Expert Opin Biol Ther. 2007 Nov;7(11):1647-64. Review.

PMID:
17961089
46.

Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis.

Jaini R, Hannaman D, Johnson JM, Bernard RM, Altuntas CZ, Delasalas MM, Kesaraju P, Luxembourg A, Evans CF, Tuohy VK.

Mol Ther. 2006 Sep;14(3):416-22. Epub 2006 Jun 16.

47.

Enhancement of immune responses to an HBV DNA vaccine by electroporation.

Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R.

Vaccine. 2006 May 22;24(21):4490-3. Epub 2005 Aug 19.

PMID:
16140436
49.

Probing the activation requirements for naive CD8+ T cells with Drosophila cell transfectants as antigen presenting cells.

Cai Z, Brunmark AB, Luxembourg AT, Garcia KC, Degano M, Teyton L, Wilson I, Peterson PA, Sprent J, Jackson MR.

Immunol Rev. 1998 Oct;165:249-65. Review.

PMID:
9850865
50.

Requirements for stimulating naive CD8+ T cells via signal 1 alone.

Luxembourg AT, Brunmark A, Kong Y, Jackson MR, Peterson PA, Sprent J, Cai Z.

J Immunol. 1998 Nov 15;161(10):5226-35.

Supplemental Content

Loading ...
Support Center